Your search for comorbidities returned 22 results

Researchers sought to determine whether screening vs no screening for atrial fibrillation could reduce morbidity and mortality.

Using data on patients with existing atrial fibrillation (AF), researchers analyzed the link between diabetes with the AF phenotype and cardiac and neurologic comorbidities.

Using an IV sotalol formulation, researchers were able to develop a safe and cost-effective option for administering the antiarrhythmic drug.

Researchers at AHA 2021 presented their findings from a study that compared CVD risk factors and in-hospital outcomes in young, Black US adults a decade apart.

Authors performed a systematic review of current evidence for the use of the Atrial Fibrillation Better Care (ABC) pathway and its effect on clinical outcomes.

Researchers sought to determine whether the stress of a contentious political election increases the risk of arrhythmia in patients with known susceptibility.

A systematic review and meta-analysis was conducted to look at the effects of body mass index on atrial fibrillation‐related outcomes in anticoagulated patients.

Sodium-glucose cotransporter 2 inhibitors use may reduce cardiac arrhythmia risk, including the risk for atrial fibrillation.

In patients hospitalized for COPD exacerbation, the presence of atrial fibrillation may increase the risk of in-hospital mortality.

Patients with atrial fibrillation who use anticoagulants and have a history of gastrointestinal bleeding may be at higher risk for subsequent major gastrointestinal bleeding.